Now that the Implandata Ophthalmic Products has received approval to commercialize its implantable glaucoma-monitoring device in the European Union, it’s setting its sights on lining up funding to launch US trials in 2018, company managing director Max Ostermeier tells OIS Weekly in an exclusive podcast. It’s no coincidence that the company’s initials – IOP – … Continue reading With CE Mark for Glaucoma Microsensor in Pocket, Implandata Looks to US